209 related articles for article (PubMed ID: 31048013)
1. Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety.
Lai VWY; Chen G; Gin D; Sinclair R
J Am Acad Dermatol; 2019 Sep; 81(3):694-701. PubMed ID: 31048013
[TBL] [Abstract][Full Text] [Related]
2. Impact of cyclosporin treatment on health-related quality of life of patients with alopecia areata.
Lai VWY; Chen G; Sinclair R
J Dermatolog Treat; 2021 Mar; 32(2):250-257. PubMed ID: 31389731
[TBL] [Abstract][Full Text] [Related]
3. Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study.
Strober BE; Menon K; McMichael A; Hordinsky M; Krueger G; Panko J; Siu K; Lustgarten JL; Ross EK; Shapiro J
Arch Dermatol; 2009 Nov; 145(11):1262-6. PubMed ID: 19917955
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial.
Tosti A; Iorizzo M; Botta GL; Milani M
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1243-7. PubMed ID: 17062039
[TBL] [Abstract][Full Text] [Related]
5. Topical calcipotriol vs narrowband ultraviolet B in treatment of alopecia areata: a randomized-controlled trial.
El Taieb MA; Hegazy EM; Ibrahim HM; Osman AB; Abualhamd M
Arch Dermatol Res; 2019 Oct; 311(8):629-636. PubMed ID: 31236672
[TBL] [Abstract][Full Text] [Related]
6. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata.
Mikhaylov D; Pavel A; Yao C; Kimmel G; Nia J; Hashim P; Vekaria AS; Taliercio M; Singer G; Karalekas R; Baum D; Mansouri Y; Lebwohl MG; Guttman-Yassky E
Arch Dermatol Res; 2019 Jan; 311(1):29-36. PubMed ID: 30417279
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Methotrexate Alone vs Methotrexate Plus Low-Dose Prednisone in Patients With Alopecia Areata Totalis or Universalis: A 2-Step Double-Blind Randomized Clinical Trial.
Joly P; Lafon A; Houivet E; Donnadieu N; Richard MA; Dupuy A; Delaporte E; Bernard P; Machet L; Tosti A; Del Marmol V; Grimalt R; de Viragh PA; Benichou J; Chosidow O; Assouly P; Reygagne P
JAMA Dermatol; 2023 Apr; 159(4):403-410. PubMed ID: 36884234
[TBL] [Abstract][Full Text] [Related]
8. Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis.
Coronel-Pérez IM; Rodríguez-Rey EM; Camacho-Martínez FM
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):481-5. PubMed ID: 20028444
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of platelet-rich plasma on hair regrowth and lesional T-cell cytokine expression in alopecia areata: A randomized observer-blinded, placebo-controlled, split-head pilot study.
Gupta V; Parihar AS; Sharma VK; Jain S; Singh V; Khanna N
J Am Acad Dermatol; 2021 May; 84(5):1321-1328. PubMed ID: 33359595
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Novel Topical Liposomal Formulation of Cyclosporine in Mild to Moderate Stable Plaque Psoriasis: A Randomized Clinical Trial.
Kumar R; Dogra S; Amarji B; Singh B; Kumar S; Sharma ; Vinay K; Mahajan R; Katare OP
JAMA Dermatol; 2016 Jul; 152(7):807-15. PubMed ID: 27096709
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata.
Kim BJ; Min SU; Park KY; Choi JW; Park SW; Youn SW; Park KC; Huh CH
J Dermatolog Treat; 2008; 19(4):216-20. PubMed ID: 18608727
[TBL] [Abstract][Full Text] [Related]
12. A randomized comparative study of the efficacy of topical latanoprost versus topical betamethasone diproprionate lotion in the treatment of localized alopecia areata.
Bhat S; Handa S; De D
Indian J Dermatol Venereol Leprol; 2021; 87(1):42-48. PubMed ID: 33580923
[TBL] [Abstract][Full Text] [Related]
13. Use of adapalene in alopecia areata: Efficacy and safety of mometasone furoate 0.1% cream versus combination of mometasone furoate 0.1% cream and adapalene 0.1% gel in alopecia areata.
Unal M
Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29193637
[TBL] [Abstract][Full Text] [Related]
14. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B; Guttman-Yassky E; Peeva E; Banerjee A; Sinclair R; Pavel AB; Zhu L; Cox LA; Craiglow B; Chen L; Banfield C; Page K; Zhang W; Vincent MS
J Am Acad Dermatol; 2021 Aug; 85(2):379-387. PubMed ID: 33757798
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial.
Ghassemi M; Yazdanian N; Behrangi E; Jafari M; Goodarzi A
Dermatol Ther; 2022 Dec; 35(12):e15943. PubMed ID: 36257912
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY; Craiglow BG; Dai F; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows.
Faghihi G; Andalib F; Asilian A
Eur J Dermatol; 2009; 19(6):586-7. PubMed ID: 19620039
[TBL] [Abstract][Full Text] [Related]
18. Higher concentrations of dithranol appear to induce hair growth even in severe alopecia areata.
Ngwanya MR; Gray NA; Gumedze F; Ndyenga A; Khumalo NP
Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28598005
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of topical dithranol (Dithrocream
Daunton A; Harries M
Br J Dermatol; 2019 May; 180(5):1246-1247. PubMed ID: 30536990
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of topical calcipotriol in management of alopecia areata: A pilot study.
Narang T; Daroach M; Kumaran MS
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28133875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
